VolitionRX Ltd：一旦获准报销，预计Nu.q将于2026年第四季度在法国投入常规临床使用_老虎社区_美港股上老虎

VolitionRX Ltd：一旦获准报销，预计Nu.q将于2026年第四季度在法国投入常规临床使用

美股速递01-30

VolitionRX Ltd宣布，其创新产品Nu.q在获得报销批准后，预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1127130875?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-30 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127130875","market":"us","top_or_hot":-1,"title":"VolitionRX Ltd：一旦获准报销，预计Nu.q将于2026年第四季度在法国投入常规临床使用","media":"美股速递","content":"<p>VolitionRX Ltd宣布，其创新产品Nu.q在获得报销批准后，预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VolitionRX Ltd：一旦获准报销，预计Nu.q将于2026年第四季度在法国投入常规临床使用</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVolitionRX Ltd：一旦获准报销，预计Nu.q将于2026年第四季度在法国投入常规临床使用\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-01-30 21:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VolitionRX Ltd宣布，其创新产品Nu.q在获得报销批准后，预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VNRX","symbol_name":"VolitionRX Ltd","start_time":0,"source_url":"","article_id":"1127130875","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127130875","pubTimestamp":1769781191,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VolitionRX Ltd宣布，其创新产品Nu.q在获得报销批准后，预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"VNRX":"VolitionRX Ltd","BK4198":"医疗保健用品"},"translate_title":"VolitionRX Ltd: Nu.q is expected to enter routine clinical use in France in Q4 2026 once reimbursement is approved","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNRX":1},"content_text":"VolitionRX Ltd宣布，其创新产品Nu.q在获得报销批准后，预计将于2026年第四季度在法国正式进入常规临床应用阶段。这一进展标志着公司在推动癌症早期检测技术普及方面迈出关键一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}